Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution

Blood

Volumn 99, Issue 7, 2002, Pages 2586-2591

  Klangsinsirikul, Phennapha ^a,b   Ian Carter, G ^b   Byrne, Jennifer L ^a,b   Hale, Geoff ^a,b   Russell, Nigel H ^a,b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CAMPATH 1G; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; GLYCOPROTEIN P 15095; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALLOGRAFT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CHIMERA; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; T LYMPHOCYTE;

EID: 0036530011     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.7.2586     Document Type: Article

References (35)

1. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
2. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
3. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
4. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1)
5. Development of a simplified counterflow centrifugation elutriation procedure for depletion of lymphocytes from human bone marrow
6. Graftversus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow
7. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation
8. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Importance of a graft-versus-leukaemia effect
9. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes
10. + cells from HLA-mismatched donors
11. + selected cells in mismatched stem cell transplantation: A single centre experience of haploidentical peripheral blood stem cell transplantation
12. Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement
13. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection
14. Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes
15. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies
16. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
17. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells
18. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: Major prognostic impact of HLA class I identity between donor and recipient
19. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia
20. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: An effective regimen with low procedure-related toxicity
21. Prevention of graft versus host disease by inactivation of host antigen-presenting cells
22. The dendritic cell system and its role in immunogenicity
23. Non-lineage antigens and dendritic cells functional studies: The Cmrf-56 monoclonal antibody identifies dendritic cells after brief culture of human peripheral blood mononuclear cells
24. + peripheral blood dendritic cells are differentially regulated by cytokines
25. The use of 7-amino actinomycin D in identifying apoptosis: Simplicity of use and broad spectrum of application compared with other techniques
26. Detection of DNA sequence polymorphisms by enzymatic amplification and direct genomic sequencing
27. A second-generation linkage map of the human genome
28. Comparative serial quantitative measurements of chimaerism following unmanipulated allogeneic transplantation of peripheral blood stem cells and bone marrow
29. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation
30. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature
31. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon
32. Reciprocal control of T helper cell and dendritic cell differentiation
33. Dendritic cell chimerism after allogeneic bone marrow transplantation